Drug intelligence / Profile preview

KH617 + temozolomide

Development stage: Unknown
Lead developer: Sichuan Honghe Biotechnology
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

KH617 + temozolomide is a combination product under investigation for the treatment of recurrent glioblastoma. KH617 is an investigational injectable agent, and temozolomide is an established oral alkylating agent. Temozolomide acts by alkylating DNA at the O6 and N7 positions of guanine, causing DNA strand breaks and apoptosis in tumor cells with impaired DNA repair mechanisms[2][4]. The precise mechanism of action for KH617 is not disclosed in available public sources, but it is being tested in combination with temozolomide in Phase 2 clinical trials for its synergistic efficacy and safety[1].

Brand names: Temomedac
Other names: TMZKH617 + TMZ

Targets

ORM1 (Alpha-1-acid glycoprotein 1)DNA

Beyond the preview

Go deeper on KH617 + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH617 + temozolomide.

Explore the full profile